EMA and its new host country have finalized the terms of the agency’s relocation to Amsterdam.
On April 24, 2018, the European Medicines Agency (EMA) announced that the text for the Seat Agreement between the agency and the Netherlands has been finalized. The agreement describes how EMA will be treated by the Dutch government when EMA relocates to Amsterdam. The agency also announced that the Dutch Council of Ministers had agreed to sign the agreement on April 13. The agreement will be signed after the legislative process on the relocation is completed by the European Council, the European Parliament, and the European Commission.
According to EMA, the Seat Agreement allows EMA to function independently in the Netherlands. Similar agreements apply to other EU agencies located in the Netherlands.
“As this transition needs to be supported by EMA staff in the Netherlands, a timely signing of the agreement would make sure that EMA staff and their families have clarity on their treatment and can settle in the Netherlands. This is especially important for staff who want to move before the start of the next school year,” the agency stated in a press release.
Source: EMA
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
New Cancer Research and Treatment Center in Development in London
May 1st 2025Aviva Capital Partners and developer Socius are investing £1 billion in a 12-acre site to be located at the London Cancer Hub next to The Institute of Cancer Research, London and The Royal Marsden NHS Foundation Trust’s Sutton site.
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.